PHASE II PILOT STUDYOF VELCADE® (BORTEZOMIB) IN COMBINATION WITH TEMOZOLOMIDE AND REGIONAL RADIATION THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME

被引：0
|
作者：
Kong, Xiao-Tang [1 ]
Green, Stacey [1 ]
Filka, Emese [1 ]
Green, Richard [2 ]
Yong, William [1 ]
Nghiemphu, Phioanh [1 ]
Cloughesy, Timothy [1 ]
Lai, Albert [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Kaiser Permanente Los Angeles, Los Angeles, CA USA
来源：
NEURO-ONCOLOGY | 2013年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [21] Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study
    Nicholas, M. K.
    Lucas, R. V.
    Arzbaecher, J.
    Paleologos, N.
    Krouwer, H.
    Malkin, M.
    Omar, A.
    Vick, N. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
    Rosenfeld, Myrna R.
    Ye, Xiaobu
    Supko, Jeffrey G.
    Desideri, Serena
    Grossman, Stuart A.
    Brem, Steven
    Mikkelson, Tom
    Wang, Daniel
    Chang, Yunyoung C.
    Hu, Janice
    McAfee, Quentin
    Fisher, Joy
    Troxel, Andrea
    Piao, Shengfu
    Heitjan, Daniel F.
    Tan, Kay See
    Pontiggia, Laura
    O'Dwyer, Peter J.
    Davis, Lisa E.
    Amaravadi, Ravi K.
    AUTOPHAGY, 2014, 10 (08) : 1359 - 1368
  • [23] Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
    Prados, Michael D.
    Chang, Susan M.
    Butowski, Nicholas
    DeBoer, Rebecca
    Parvataneni, Rupa
    Carliner, Hannah
    Kabuubi, Paul
    Ayers-Ringler, Jennifer
    Rabbitt, Jane
    Page, Margaretta
    Fedoroff, Anne
    Sneed, Penny K.
    Berger, Mitchel S.
    McDermott, Michael W.
    Parsa, Andrew T.
    Vandenberg, Scott
    James, C. David
    Lamborn, Kathleen R.
    Stokoe, David
    Haas-Kogan, Daphne A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 579 - 584
  • [24] Phase II trial of erlotinib with temozolomide and concurrent radiation therapy post-operatively in patients with newly diagnosed glioblastoma multiforme
    Pecreboom, DM
    Brewer, C
    Stevens, GHJ
    Suh, JH
    Toms, S
    Vogelbaum, MA
    Barnett, GH
    NEURO-ONCOLOGY, 2004, 6 (04) : 379 - 379
  • [25] Phase II Trial of Hypofractionated IMRT With Temozolomide for Patients With Newly Diagnosed Glioblastoma Multiforme
    Reddy, Krishna
    Damek, Denise
    Gaspar, Laurie E.
    Ney, Douglas
    Waziri, Allen
    Lillehei, Kevin
    Stuhr, Kelly
    Kavanagh, Brian D.
    Chen, Changhu
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : 655 - 660
  • [26] Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
    Butowski, Nicholas
    Chang, Susan M.
    Lamborn, Kathleen R.
    Polley, Mei-Yin
    Pieper, Russell
    Costello, Joseph F.
    Vandenberg, Scott
    Parvataneni, Rupa
    Nicole, Angelina
    Sneed, Patricia K.
    Clarke, Jennifer
    Hsieh, Emily
    Costa, Bruno M.
    Reis, Rui M.
    Hristova-Kazmierski, Maria
    Nicol, Steven J.
    Thornton, Donald E.
    Prados, Michael D.
    NEURO-ONCOLOGY, 2011, 13 (12) : 1331 - 1338
  • [27] LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ranjan, Tulika
    Desjardins, Annick
    Peters, Katherine B.
    Alderson, Lloyd
    Kirkpatrick, John
    Herndon, James, II
    Bailey, Leighann
    Sampson, John
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James
    NEURO-ONCOLOGY, 2012, 14 : 81 - 82
  • [28] PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Dixit, Karan
    Kumthekar, Priya
    Kruser, Timothy
    Bloch, Orin
    Chandler, James
    Tate, Matthew
    Raizer, Jeffrey
    NEURO-ONCOLOGY, 2016, 18 : 19 - 19
  • [29] Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): Report of a Phase II trial.
    Doyle, TJ
    Mikkelsen, T
    Croteau, D
    Ali, H
    Anderson, J
    Beasse, R
    Rogers, L
    Rosenblum, M
    Ryu, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 125S - 125S
  • [30] Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma
    Butowski, N. A.
    Lamborn, K.
    Chang, S.
    Thornton, D.
    DeBoer, R.
    Page, M.
    Rabbitt, J.
    Parvanateni, R.
    Kivett, V.
    Nicol, S.
    Prados, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345